IPSC · Century Therapeutics
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Market Cap
211.6M
52 Wk Range
$0.48 - $3.04
Previous Close
$1.32
Open
$1.32
Volume
916,612
Day Range
$1.16 - $1.32
Enterprise Value
160M
Cash
117.2M
Avg Qtr Burn
-22.23M
Insider Ownership
8.10%
Institutional Own.
89.96%
Qtr Updated
Sep 30th 2026
